Assistant Professor at MD Anderson Cancer Center. Lymphoma/Myeloma Department. Focus on multiple myeloma and cellular therapies. Tweets and opinions are my own.
Houston, TX
Joined January 2011
- Tweets345
- Following499
- Followers502
- Likes787
Pinned Tweet
Our work on bispecifics in plasma cell leukemia is now published. Talquetamab showed markedly better outcomes than BCMA bispecifics in patients with active PCL (≥5% circulating PCs), including those who were BCMA-naive. With virtually no prospective trial data in this space, this striking signal may help inform treatment choice. authors.elsevier.com/sd/arti… #mmsm @DrKrinaPatel @MDAndersonnews @MyelomaSLC @RahulBanerjeeMD @Transplant_Doc
Mahmoud Gaballa retweeted
BCMA×GPRC5D dual-targeted CAR-T therapy BMS-986453 showed >90% response rates at two dose levels in ongoing first-in-human early-phase trial, w/ 100% response 100% MRD-negativity in BCMA/GPRC5d-naïve pts --- Doris Hansen, MD #IMS26
Mahmoud Gaballa retweeted
Mahmoud Gaballa retweeted
Congratulations to the 2026 IMS Global Leadership Opportunity (GLO) Cohort at #IMS26.
Mahmoud Gaballa retweeted
#Myeloma Paper of the Day: TRIMM-2 study of teclistamab & daratumumab in RRMM finds ORR 68.9% (CR or better 44.3%); median DOR not reached; median PFS 26.3 mos; most common TEAEs = infxns, CRS, neutropenia, anemia; grade 3/4 TEAEs in 93.4%, 7 died: pubmed.ncbi.nlm.nih.gov/4268…. #mmsm
Mahmoud Gaballa retweeted
Agree with Dr. Landau @MSKCancerCenter #ASH25
You cannot make a diagnosis of “MGRS” without a renal biopsy.
And on a renal biopsy you need to have proof of a specific pathology (see Table) that’s attributable to a monoclonal protein.
Mahmoud Gaballa retweeted
Tec Dara for transplant ineligible newly diagnosed myeloma. Very impressive results with early step down to Q4W Tec dosing and high IVIG use to make tolerable. Good to hear that plans to move to Q8w Tec and fixed duration #ASH25
Mahmoud Gaballa retweeted
Real world outcomes of bispecific T-cell engagers in plasma cell leukemia [Nov 3, 2025] @mahrefat et al. #ASH25 abs25-4651 PID 823
meetings-api.hematology.org/… #mmsm 122 PCL pts from 15 US centers
Mahmoud Gaballa retweeted
1/ Making #ASH25 myeloma abstract list getting tougher than ever!
My rubric for this 'Top 10' list: Abstracts that challenge how I think about #MMsm.. well worth the trek to Orlando!
Kudos to all authors for excellent research, including of many abstracts not mentioned here 👏
Mahmoud Gaballa retweeted
Great to see this paper out! #mmsm
Sequential targeting of GPRC5D and BCMA in MM with talquetamab bridging is a great strategy
✅ effective
✅ no increased toxicity with CAR-T
🎉Finally out🎉
Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity
@BloodPortfolio
ashpublications.org/blood/ar…
#mmsm
Our open access article “BCMA-directed CAR T-cell Therapy in patients with multiple myeloma and CNS involvement” is now available online (link below). #mmsm #cart @DrKrinaPatel
authors.elsevier.com/sd/arti…
Mahmoud Gaballa retweeted
#Myeloma Paper of the Day: International multi-center observational study comparing cilta-cel to ide-cel for for relapsed or refractory myeloma notes former has better ORR & CR rates, and better PFS & OS but more severe (grade 3 or 4) CRS and ICANS: pubmed.ncbi.nlm.nih.gov/3982…. #mmsm
Mahmoud Gaballa retweeted
#Myeloma Paper of the Day: BCMA-directed CAR T-cell therapy in myeloma pts w/ CNS involvement gives ORR of 80%, VGPR or better 70%, & CNS response 100%, median OS and PFS of 13.3 & 6.3 months, suggesting consideration for post-CART maintenance: pubmed.ncbi.nlm.nih.gov/3972…. #mmsm
Proud of our work re outcomes of BCMA CART in CNS MM #mmsm #cart @DrKrinaPatel @BloodAdvances ashpublications.org/bloodadv…
Mahmoud Gaballa retweeted
This was a very practical poster at #ASH24, looking at prolonged dosing intervals of teclistamab, which is very relevant as dosing of tec (and other bispecific antibodies) moves to q4 week (or even longer intervals).
New recommendation: if dosing interval ≤62 days, no need to repeat step up dosing!
@AlGarfall doi.org/10.1182/blood-2024-2…
Mahmoud Gaballa retweeted
Fantastic job by #OrenPasvolsky presenting RWE for the safe and effective use of teclistamab for older RRMM patients (one of our vulnerable groups)!
Mahmoud Gaballa retweeted
#ASH24 #mmsm @ASH_hematology
Monoclonal Gammopathies: When the Clone Is More Than a Positive Laboratory Finding How to treat MGRS
Classification of MGRS- Related Renal Diseases
Mahmoud Gaballa retweeted
#ASH24 Sustained MRD negativity for 3 years can guide discontinuation of Len maintenance after ASCT in MM. 92% patients remained MRD-ve 30 months after maintenance discontinuation #mmsm #bmtsm @thanosdimop ash.confex.com/ash/2024/webp…